Related references
Note: Only part of the references are listed.Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
A. C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-CD20 as the B-cell a targeting agent in a combined therapy to modulate anti-factor VIII immune responses hemophilia A inhibitor mice
Chao Lien Liu et al.
FRONTIERS IN IMMUNOLOGY (2014)
Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions
Etiena Basner-Tschakarjan et al.
FRONTIERS IN IMMUNOLOGY (2014)
AAV vectors vaccines against infectious diseases
Karen Nieto et al.
FRONTIERS IN IMMUNOLOGY (2014)
Pre-clinical assessment of immune responses to adeno-associated virus (AAV) vectors
Etiena Basner-Tschakarjan et al.
FRONTIERS IN IMMUNOLOGY (2014)
Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors
Yu-Shan Tseng et al.
FRONTIERS IN IMMUNOLOGY (2014)
Glucocorticoid-induced TNF receptor family-related protein ligand is requisite for optimal functioning of regulatory CD4+ T cells
Gongxian Liao et al.
FRONTIERS IN IMMUNOLOGY (2014)
Immune responses to AAV-vectors, the Glybera example from bencn to bedside
Valerie Ferreira et al.
FRONTIERS IN IMMUNOLOGY (2014)
Gene therapy enters the pharma market: The short story of a long journey
Hildegard Buening
EMBO MOLECULAR MEDICINE (2013)
CpG-depleted adeno-associated virus vectors evade immune detection
Susan M. Faust et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Immunology of AAV-mediated gene transfer in the eye
Keiman Willett et al.
FRONTIERS IN IMMUNOLOGY (2013)
Immunological monitoring to rationally guide AAV gene therapy
Cedrik Michael Britten et al.
FRONTIERS IN IMMUNOLOGY (2013)
Humoral immune response to AAV
Roberto Calcedo et al.
FRONTIERS IN IMMUNOLOGY (2013)
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer
George Buchlis et al.
BLOOD (2012)
Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors
Marianna Hoesel et al.
HEPATOLOGY (2012)
MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV
Muriel Sudres et al.
MOLECULAR THERAPY (2012)
The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver
Ashley T. Martino et al.
BLOOD (2011)
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
Federico Mingozzi et al.
NATURE REVIEWS GENETICS (2011)
Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity
Melissa Bartel et al.
FRONTIERS IN MICROBIOLOGY (2011)
The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice
Jiangao Zhu et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Emerging role of regulatory T cells in gene transfer
Ou Cao et al.
CURRENT GENE THERAPY (2007)
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
F Mingozzi et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo
DM McCarty et al.
GENE THERAPY (2003)
Share Paper
